Lung Cancer Clinical Trial
Official title:
Phase I Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies
The goal of this clinical research study is to study the safety of giving larger daily doses of proton radiation therapy than the standard dose levels given to treat lung cancer. Researchers want to find the highest daily dose of proton radiation that can be given without having to stop therapy due to side effects.
Proton Therapy:
Proton therapy is a type of radiation that is designed to lower the amount of radiation given
to the healthy tissue around the tumor by using a more focused beam of radiation.
Radiation Dose Levels:
If you are found to be eligible to take part in this study, you will be assigned to receive 1
of 3 doses of radiation therapy, based on when you joined the study. The first group of at
least 3 participants will receive the lowest total radiation dose. If the first dose is
tolerated well by the first group of participants in this study, then the next group of
participants will receive the second, higher dose of radiation. If this dose is tolerated,
then a third group will be treated at the highest dose.
Practice Visit:
You will have a "practice" radiation visit to plan how the radiation will be given, about 1
week before therapy. This practice visit should take about 1-2 hours. At this visit, you will
have a CT scan of the chest that will be used by the study staff to plan your proton therapy.
A mold (made of the type of material used for casts) will also be made around your body that
will be used to help you remain still during radiation therapy. Marks will be made on your
skin to help position your body correctly for the radiation therapy. These marks may be
permanent or temporary. If temporary marks are washed off, they will be replaced.
Proton Therapy Visits:
About 1 week after the practice radiation visit, you will begin receiving radiation therapy.
At each visit, you will lie down in the mold of your body that was made at the practice
visit, and you will be lined up for radiation therapy using the marks made on your skin at
the practice visit.
You will receive radiation therapy every weekday (Monday-Friday) for about 3 weeks. Each
radiation session should last about 45-60 minutes.
Study Tests:
Each week while you are receiving radiation therapy, you will be asked about any side effects
you may be having. Your medical history will be recorded, and you will have a physical exam.
If your doctor thinks it is needed, blood (about 2 tablespoons each time) will be drawn for
routine tests, and/or you may have CT scans to check the status of the tumor.
Length of Therapy:
You will receive proton radiation therapy for about 3 weeks. The radiation therapy will be
stopped early if the disease gets worse or intolerable side effects occur.
Follow-up Visits:
About 6 weeks after your last dose of proton radiation, you will have a CT scan of the chest
(with a contrast agent, if possible) and a physical exam.
About 3 months after the first follow-up visit you will have a physical exam, lung function
tests, and either a PET/CT scan or CT scan of the chest to check the status of the disease.
Long-term Follow-up:
Every 3 months for the first 2 years after you finish proton therapy, every 6 months for the
next 3 years, and 1 time every year after that, you will be asked to return to the clinic for
follow-up tests. These tests may include lung function tests, imaging scans (such as a CT or
PET/CT scan), and/or an ECG. This will be up to your doctor.
This is an investigational study. At this time, it is considered investigational to give
proton radiation therapy at the dose schedule used in this study. This schedule is being used
for research purposes only.
Up to 30 patients will take part in this study. All will be enrolled at M. D. Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|